Journal
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES
Volume 39, Issue 3, Pages 267-274Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10863-007-9086-x
Keywords
Warburg effect; glycolysis; inhibitor; mitochondria; cancer therapeutics; drug resistance; reactive oxygen species (ROS); oncogene; hypoxia
Categories
Funding
- NCI NIH HHS [CA109041, CA100428, CA085563] Funding Source: Medline
Ask authors/readers for more resources
Increased aerobic glycolysis in cancer, a phenomenon known as the Warburg effect, has been observed in various tumor cells and represents a major biochemical alteration associated with malignant transformation. Although the exact molecular mechanisms underlying this metabolic change remain to be elucidated, the profound biochemical alteration in cancer cell energy metabolism provides exciting opportunities for the development of therapeutic strategies to preferentially kill cancer cells by targeting the glycolytic pathway. Several small molecules capable of inhibiting glycolysis in experimental systems have been shown to have promising anticancer activity in vitro and in vivo. This review article provides a brief summary of our current understanding of the Warburg effect, the underlying mechanisms, and its influence on the development of therapeutic strategies for cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available